These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 10227700

  • 1. Grapefruit juice activates P-glycoprotein-mediated drug transport.
    Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ.
    Pharm Res; 1999 Apr; 16(4):478-85. PubMed ID: 10227700
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells.
    Takanaga H, Ohnishi A, Matsuo H, Sawada Y.
    Biol Pharm Bull; 1998 Oct; 21(10):1062-6. PubMed ID: 9821810
    [Abstract] [Full Text] [Related]

  • 3. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
    Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR.
    Pharm Res; 1999 Mar; 16(3):408-14. PubMed ID: 10213372
    [Abstract] [Full Text] [Related]

  • 4. The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein.
    Di Marco MP, Edwards DJ, Wainer IW, Ducharme MP.
    Life Sci; 2002 Jul 26; 71(10):1149-60. PubMed ID: 12095536
    [Abstract] [Full Text] [Related]

  • 5. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
    Raeissi SD, Hidalgo IJ, Segura-Aguilar J, Artursson P.
    Pharm Res; 1999 May 26; 16(5):625-32. PubMed ID: 10350002
    [Abstract] [Full Text] [Related]

  • 6. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.
    Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB.
    J Clin Invest; 1997 May 15; 99(10):2545-53. PubMed ID: 9153299
    [Abstract] [Full Text] [Related]

  • 7. Role of human CYP3A and P-glycoprotein on the absorption of drugs.
    van de Waterbeemd H.
    Eur J Pharm Sci; 2000 Nov 15; 12(1):1. PubMed ID: 11121728
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.
    Eagling VA, Profit L, Back DJ.
    Br J Clin Pharmacol; 1999 Oct 15; 48(4):543-52. PubMed ID: 10583025
    [Abstract] [Full Text] [Related]

  • 9. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH.
    Int J Cancer; 2013 May 15; 132(10):2439-47. PubMed ID: 23090875
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4.
    Ohnishi A, Matsuo H, Yamada S, Takanaga H, Morimoto S, Shoyama Y, Ohtani H, Sawada Y.
    Br J Pharmacol; 2000 Jul 15; 130(6):1369-77. PubMed ID: 10903978
    [Abstract] [Full Text] [Related]

  • 13. 6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein.
    Edwards DJ, Fitzsimmons ME, Schuetz EG, Yasuda K, Ducharme MP, Warbasse LH, Woster PM, Schuetz JD, Watkins P.
    Clin Pharmacol Ther; 1999 Mar 15; 65(3):237-44. PubMed ID: 10096255
    [Abstract] [Full Text] [Related]

  • 14. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
    Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ.
    Cancer Res; 1999 Aug 15; 59(16):3944-8. PubMed ID: 10463589
    [Abstract] [Full Text] [Related]

  • 15. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4.
    Takanaga H, Ohnishi A, Yamada S, Matsuo H, Morimoto S, Shoyama Y, Ohtani H, Sawada Y.
    J Pharmacol Exp Ther; 2000 Apr 15; 293(1):230-6. PubMed ID: 10734174
    [Abstract] [Full Text] [Related]

  • 16. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
    Cummins CL, Jacobsen W, Benet LZ.
    J Pharmacol Exp Ther; 2002 Mar 15; 300(3):1036-45. PubMed ID: 11861813
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.
    Wandel C, Kim RB, Guengerich FP, Wood AJ.
    Drug Metab Dispos; 2000 Aug 15; 28(8):895-8. PubMed ID: 10901697
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.